



## Aastrom to Present at the Stifel Nicolaus Healthcare Conference

ANN ARBOR, Mich., Sept. 1, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will speak at the Stifel Nicolaus Healthcare Conference, which is being held September 7-9, 2011, at the Four Seasons Hotel in Boston, Massachusetts.

The Aastrom presentation will take place from 3:15 P.M. to 3:45 P.M. (EDT) on September 7, 2011. The presentation will be webcast live and will also be accessible in archive until October 7, 2011, beginning one hour after the presentation. The URL for live and archived access to the presentation is <http://www.veracast.com/webcasts/stifel/healthcare2011/81113558.cfm>. Participants should allow approximately five to ten minutes prior to the presentation start time to visit the site and download any streaming media software needed to listen to the webcast.

### About Aastrom Biosciences

Aastrom Biosciences is developing patient-specific, expanded multicellular therapies for use in the treatment of severe, chronic cardiovascular diseases. The company's proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced ixmyelocel-T into late-stage clinical development, including a planned Phase 3 clinical program to study patients with critical limb ischemia and two Phase 2 clinical trials in patients with dilated cardiomyopathy. For more information, please visit Aastrom's website at [www.aastrom.com](http://www.aastrom.com).

The Aastrom Biosciences, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=3663>

*This document contains forward-looking statements, including, without limitation, statements concerning clinical trial plans and progress, objectives and expectations, clinical activity timing, intended product development, the performance and contribution of certain individuals and expected timing of collecting and analyzing treatment data, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "could," "may," or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with clinical trial and product development activities, regulatory approval requirements, competitive developments, and the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual or Transition Report on Form 10-K or 10-K/T, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. These forward-looking statements reflect management's current views and Aastrom does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.*

CONTACT: Media contact

Bill Berry

Berry & Company

[bberry@berrypr.com](mailto:bberry@berrypr.com)

(212) 253-8881

Investor contact

Danielle Spangler

The Trout Group

[dspangler@troutgroup.com](mailto:dspangler@troutgroup.com)

(646) 378-2924